


## PAPER

View Article Online  
View Journal


Cite this: DOI: 10.1039/d2bm00827k

# Alveolar epithelial cells and microenvironmental stiffness synergistically drive fibroblast activation in three-dimensional hydrogel lung models†

Thomas Caracena,<sup>‡a</sup> Rachel Blomberg,<sup>‡a</sup> Rukshika S. Hewawasam,<sup>a</sup> Zoe E. Fry,<sup>a</sup> David W. H. Riches<sup>b,c,d,e</sup> and Chelsea M. Magin  <sup>\*,a,c,f</sup>

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease that progressively and irreversibly alters the lung parenchyma, eventually leading to respiratory failure. The study of this disease has been historically challenging due to the myriad of complex processes that contribute to fibrogenesis and the inherent difficulty in accurately recreating the human pulmonary environment *in vitro*. Here, we describe a poly (ethylene glycol) PEG hydrogel-based three-dimensional model for the co-culture of primary murine pulmonary fibroblasts and alveolar epithelial cells that reproduces the micro-architecture, cell placement, and mechanical properties of healthy and fibrotic lung tissue. Co-cultured cells retained normal levels of viability up to at least three weeks and displayed differentiation patterns observed *in vivo* during IPF progression. Interrogation of protein and gene expression within this model showed that myofibroblast activation required both extracellular mechanical cues and the presence of alveolar epithelial cells. Differences in gene expression indicated that cellular co-culture induced TGF- $\beta$  signaling and proliferative gene expression, while microenvironmental stiffness upregulated the expression of genes related to cell–ECM interactions. This biomaterial-based cell culture system serves as a significant step forward in the accurate recapitulation of human lung tissue *in vitro* and highlights the need to incorporate multiple factors that work together synergistically *in vivo* into models of lung biology of health and disease.

Received 24th May 2022,  
Accepted 29th October 2022  
DOI: 10.1039/d2bm00827k  
rsc.li/biomaterials-science

## Introduction

Idiopathic pulmonary fibrosis (IPF) is a debilitating interstitial lung disease marked by progressive stiffening of the pulmonary extracellular matrix (ECM), which impairs gas exchange, reduces compliance, and leads to respiratory failure within 3 to 5 years.<sup>1</sup> The only FDA-approved drug treatments for IPF slow disease progression but do not reverse altered lung mechanics and function.<sup>2–4</sup> Mechanistic studies of the disease indicate that repeated injury to alveolar epithelial type II (ATII) cells induces differentiation into alveolar epithelial type I (ATI)

cells as part of normal re-epithelialization. In fibrosis, a population of KRT8+ transitional cells persists.<sup>5</sup> These KRT8+ transitional cells do not fully differentiate into ATI cells and can display a profibrotic phenotype that initiates an aberrant wound-healing response in surrounding fibroblasts. This response is mediated by secreted factors capable of inducing fibroblast migration, proliferation, and activation, such as transforming growth factor- $\beta$  (TGF- $\beta$ ), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF).<sup>6,7</sup> Over time these interactions result in pulmonary fibrosis, characterized by fibroblast differentiation into myofibroblasts, excess ECM deposition,<sup>8</sup> and local tissue stiffening. In this way, IPF progresses *via* a positive feedback loop where an uncontrolled healing process results in widespread ECM remodeling and the remodeled ECM activates nearby fibroblasts.<sup>9,10</sup> While these results are consistent with previous studies reporting on the influence of ECM stiffness on fibroblasts,<sup>10–14</sup> few studies have investigated the influence of local stiffening on alveolar epithelial cells<sup>12,15</sup> and how these responses may also reinforce the progression of fibrosis. Therefore, we engineered a biomaterial-based lung tissue model to enable study of both the cellular crosstalk dynamics within the distal lung and changes in microenvironmental mechanical properties during the initiation of fibrosis.

<sup>a</sup>Department of Bioengineering, University of Colorado, Denver | Anschutz Medical Campus, USA. E-mail: Chelsea.Magin@cuanschutz.edu

<sup>b</sup>Program in Cell Biology, Department of Pediatrics, National Jewish Health, USA

<sup>c</sup>Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Anschutz Medical Campus, USA

<sup>d</sup>Department of Research, Veterans Affairs Eastern Colorado Health Care System, USA

<sup>e</sup>Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, USA

<sup>f</sup>Department of Pediatrics, University of Colorado, Anschutz Medical Campus, USA

†Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2bm00827k>

‡These authors contributed equally to this work.

There is a critical need for improved models of fibrotic disease that incorporate both ATII cells and fibroblasts in a microenvironment that closely replicates lung architecture and mechanics to facilitate the study of fibrosis and the development of new anti-fibrotic treatments. Until recently, much of our understanding of the mechanisms underlying IPF has been gained from studying cells on supra-physiologically stiff tissue culture plastic in two-dimensional (2D) monoculture or in animal models that fail to recapitulate the progressive nature of IPF in humans and make it difficult to isolate specific cell-matrix interactions, a key driver of the disease.<sup>7,16–19</sup> Advanced three-dimensional (3D) cell culture models that incorporate multiple cell types,<sup>20,21</sup> physiological substrate mechanical properties,<sup>22,23</sup> and more relevant geometries<sup>24–26</sup> are emerging to overcome these limitations. Organoids are one example of an effective tool for the study of cell-cell interactions in multicellular co-cultures as an additional factor in directing cell behavior and creating a better approximation of the native physiological environment.<sup>21,27</sup> For instance, Tan *et al.*, fabricated nascent organoids by embedding primary human bronchial epithelial cells, microvascular lung endothelial cells, and lung fibroblasts within Matrigel matrices<sup>28</sup> and demonstrated that epithelial injury was sufficient to induce fibroblast activation.<sup>21</sup> This study, while a promising step forward in the recapitulation of the native cellular environment *in vitro*, did not incorporate any control over the extracellular environment and was subject to the extracellular mechanical and chemical influences of the Matrigel cell culture substrate. In a study demonstrating the feasibility of controlling extracellular mechanical cues using decellularized ECM (dECM), Nizamoglu *et al.*, recently used a ruthenium-based crosslinker to increase the stiffness of porcine lung ECM-derived hydrogels, showing that this dECM hydrogel exhibited controllable mechanical properties and that stiffening this hydrogel increased lung fibroblast activation.<sup>23</sup> In contrast to these naturally-derived culture platforms, synthetic biomaterials such as poly(ethylene glycol) (PEG) offer enhanced customizability in exchange for a lack of innate bioactivity, providing an inert hydrogel backbone that can be extensively modified to recapitulate specific chemical and mechanical traits. Controlling polymerization parameters allows for geometric control of the resulting hydrogels, as demonstrated by Lewis *et al.*, through the use of a photodegradable PEG hydrogel to create a spherical alveolar scaffold for the culture of murine ATII cells.<sup>24</sup> Extending experimental models to encompass control over both the cellular landscape and the extracellular environment could refine fibrosis models by accounting for cell-cell and cell-matrix interactions that contribute to the progression of fibrosis.<sup>9,20,29</sup>

Here, we present a strategy for engineering 3D lung models using poly(ethylene glycol)-norbornene (PEG-NB) hydrogels that present precisely defined 3D geometries and mechanical properties that recapitulate healthy or fibrotic lung tissue to allow assessment of cross-talk between fibroblasts and ATII cells. Cell-degradable hydrogel microspheres (median diameter =  $171 \pm 42 \mu\text{m}$ ) that accurately replicate the shape and

size of human alveoli<sup>24,30</sup> were produced by emulsion polymerization. Magnetically aggregating these microspheres, along with primary murine ATII cells, formed a larger acinar structure, which was then embedded along with primary murine fibroblasts within a hydrogel that recapitulated the elastic modulus ( $E$ ) of healthy ( $E = 2\text{--}5 \text{ kPa}$ ) or fibrotic ( $E = 10\text{--}30 \text{ kPa}$ ) lung tissue.<sup>22</sup> These 3D lung models maintained cellular viability throughout the constructs over at least three weeks post embedding. Over that time, ATII cells seeded into these structures began to differentiate into ATI cells, with a significant proportion (20–25%) displaying a transitional cell phenotype marked by expression of KRT8. The proportion of activated fibroblasts was highest in the ATII-fibroblast co-cultures embedded in stiff hydrogels ( $44.0\% \pm 7.1$ ) compared to the same co-culture in a soft hydrogel ( $16.4\% \pm 2.1$ ) or fibroblast monoculture in the same stiff hydrogel ( $21.0\% \pm 1.0$ ). Gene expression analysis suggests that co-culture promotes cellular proliferation pathways, whereas microenvironmental stiffening induces an ECM-remodeling response. These results suggest that the combination of transitional ATII cells and exposure to a stiff microenvironment synergistically contribute to fibroblast activation. These findings highlight the roles played by the lung epithelium and the mechanical microenvironment in the progression of pulmonary fibrosis, demonstrating the value of this novel *in vitro* model that reconstructs cell-cell and cell-matrix interactions observed *in vivo*.

## Experimental

### Fabrication of 3D lung models

**Synthesis of PEG-NB.** The terminal residues of eight-arm 10 and 40  $\text{kg mol}^{-1}$  PEG-hydroxyl macromers (JenKem Technology) were conjugated with norbornene functional groups using a protocol adapted from an established procedure.<sup>31</sup> Briefly, poly(ethylene glycol)-hydroxyl (PEG-OH; eight-arm; 10  $\text{kg mol}^{-1}$  or 40  $\text{kg mol}^{-1}$ ; JenKem Technology) was lyophilized. Next, 5 g PEG-OH was dissolved in anhydrous dichloromethane (DCM; Sigma-Aldrich) in a flame-dried Schlenk flask under moisture-free conditions. 4-Dimethylaminopyridine (DMAP, Sigma-Aldrich; 0.24 g, 0.02 mol) was added to the flask. Pyridine (Fisher; 1.61 mL, 0.02 mol) was injected dropwise to the reaction mixture. In a separate flask, *N,N'*-dicyclohexylcarbodiimide (DCC, Fisher; 4.127 g, 0.02 mol) was dissolved in anhydrous DCM. Norbornene-2-carboxylic acid (Sigma-Aldrich; 4.9 mL, 0.04 mol) was added dropwise to the flask. The mixture was stirred at room temperature for 30 minutes and then filtered through Celite 545 (EMD Millipore). The filtrate was added to the first flask and allowed to react for 48 h in a light-protected environment. Byproducts were removed by mixing with an aqueous solution of sodium bicarbonate (Fisher). The organic phase was concentrated with rotary evaporation and the product was precipitated with diethyl ether (Sigma-Aldrich) overnight at 4 °C. The resulting polymer was dialyzed (1  $\text{kg mol}^{-1}$  MWCO, Repligen) against 3.5 L of deionized water at room tempera-

ture. The water was changed four times over 72 h, after which the polymer was lyophilized to obtain a solid white product. End-group functionalization of the resulting PEG-NB and the purity of the product were confirmed by nuclear magnetic resonance (NMR) spectroscopy. The  $^1\text{H}$  NMR spectrum was recorded on a Bruker DPX-400 FT NMR spectrometer (300 MHz) using 184 scans and 2.5 s relaxation time. Chemical shifts for protons ( $^1\text{H}$ ) were recorded as parts per million (ppm) relative to a residual solvent. Only synthesis products with greater than 90% functionalization were used (Fig. S1 and S2†).

**Emulsion polymerization of hydrogel microspheres.** PEG-NB (eight-arm  $40\text{ kg mol}^{-1}$ ) was reacted with a dithiol peptide crosslinker selected for enhanced degradation by MMP3 (Ac-GCRDGAFFALRLVDRCG-NH<sub>2</sub>; GenScript)<sup>32</sup> to facilitate degradation by ATII cells, which have been shown to secrete this enzyme *in vivo*.<sup>33,34</sup> Microspheres were formed *via* emulsion polymerization<sup>35</sup> by a photoinitiated thiol-ene reaction to create microsphere templates that enable cellular remodeling of the microenvironment.<sup>36,37</sup> A  $40\text{ kg mol}^{-1}$  macromer was selected to generate cell-degradable microspheres to form hydrogel networks with a higher average molecular weight between crosslinks to facilitate degradation. Enzyme-mediated degradation of the hydrogel microsphere templates was designed to create 3D structures resembling alveoli.

Measurement of bulk hydrogels of the same formulation as microspheres was used to assess the elastic modulus of microspheres, as previously published<sup>38</sup> and based on data demonstrating comparable results of atomic force microscopy measurements on microgels and rheology testing of bulk hydrogel.<sup>39</sup> Therefore, parallel plate rheology on bulk hydrogels from the same formulation identified a microsphere hydrogel formulation with an elastic modulus in the range of healthy lung tissue (2–5 kPa).<sup>22</sup> The PEG-NB (6 wt%) was reacted with the MMP3-degradable crosslinker at a ratio of 0.7 thiol reactive groups to NB reactive groups along with pendant peptide mimics of fibronectin (CGRGDS) and laminin (CGYIGSR; GL Biochem) (1 mM final concentrations). First, all components were dissolved individually in neutral (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; ThermoFisher) buffer and sonicated at 40 °C for 10 minutes to create stock solutions. The PEG-NB and peptide mimics were then combined in a microcentrifuge tube (Tube 1) with additional HEPES to bring the total volume to 1.5 mL. The crosslinker was combined with 15 mM tris(2-carboxyethyl) phosphine (TCEP; Sigma-Aldrich) and thiolated magnetic nanoparticles (MNPs;  $0.3\text{ mg mL}^{-1}$  final volume), synthesized as previously described<sup>40</sup> in another microcentrifuge tube (Tube 2) and sonicated at 40 °C for 10 minutes. A fluorescent label (AlexaFluor 647 c2-maleimide; ThermoFisher) was then added to Tube 2 at a final concentration of 0.02 mM and vortexed. A photoinitiator (lithium phenyl-2,4,6-trimethylbenzoylphosphine (LAP; Sigma-Aldrich) was added to Tube 1 at a final concentration of 4.5 mM and vortexed. The entire contents of Tube 2 were then added to Tube 1 and vortexed to form the aqueous component of the emulsion polymerization.

The entire 1.5 mL aqueous solution was then emulsified in 5 mL of degassed light mineral oil (Fisher Scientific) with 0.5 wt% Span80 (Sigma-Aldrich) by stirring in a Sigmacote (Sigma-Aldrich) coated glass scintillation vial at 300 rpm. The emulsification was stirred for 30 seconds and then the suspension was exposed to 365 nm UV light at  $60\text{ mW cm}^{-2}$  (Omniscure, Lumen Dynamics) for 5 minutes. Stir speed and duration were experimentally determined to yield microspheres with a median diameter of approximately  $200\text{ }\mu\text{m}$ .<sup>30</sup>

The reacted product was collected in a 50 mL conical tube, washed with fresh mineral oil, and centrifuged (Thermo Scientific Sorvall ST 40R) at 300 rpm for 3 minutes. This washing step was repeated twice for a total of three mineral oil washes. Following the final mineral oil wash, the hydrogel microspheres were washed once in 100% isopropyl alcohol (Fisher Scientific) and centrifuged at 600 rpm for 5 minutes. The supernatant was discarded, and the hydrogel microspheres were stored overnight in sterile phosphate buffered saline (PBS; Cytiva) at 4 °C. Microspheres were initially filtered through  $200\text{ }\mu\text{m}$  strainers (pluriSelect ÜberStrainer) to exclude the largest microspheres, and then successively through,  $100\text{ }\mu\text{m}$  and  $85\text{ }\mu\text{m}$  cell strainers to isolate spheres of a reproducible and physiologically relevant size range ( $d \sim 200\text{ }\mu\text{m}$ ). The microspheres able to pass through the  $100\text{ }\mu\text{m}$  strainer but that were collected in the  $85\text{ }\mu\text{m}$  strainer were used for experiments. This difference in the size of the strainer and the actual size of the microspheres was likely due to the ability of hydrogel microspheres to deform during filtration.

**Isolation of primary murine ATII cells and fibroblasts.** All animal procedures were performed in an AAALAC-accredited facility in accordance with the Guide for the Care and Use of Laboratory Animals.<sup>41</sup> All protocols were approved by the University of Colorado Denver Institutional Animal Care and Use Committee. Male and Female, 8- to 12-week-old, dual-transgenic reporter C57BL/6J mice were bred for use in these experiments. Wildtype littermates were used for alveolar epithelial type II (ATII) cell isolation and viability experiments. Primary murine ATII cells and fibroblasts were isolated from healthy mice by magnetic column isolation as follows.

For each cell isolation, a minimum of four mice were pooled, with equal numbers of male and female mice in each preparation. The lungs of freshly sacrificed mice were perfused intratracheally with a room temperature solution of dispase ( $5\text{ U mL}^{-1}$ ; Gibco) and collagenase type I ( $2\text{ mg mL}^{-1}$ ; Gibco) in PBS. A 1% low-melting point agarose solution (ThermoFisher UltraPure) was subsequently injected intratracheally and the lungs were covered in ice to form a solidified agarose plug. The lungs were removed and kept on ice in PBS until being transferred to a gentleMACS C Tube (Miltenyi Biotec) with fresh dispase/collagenase solution and incubated on a rotator at 37 °C for 20 minutes. The lungs were then mechanically dissociated on a GentleMACS Dissociator (Miltenyi Biotec) using the “m\_lung\_02.01” C Tube setting and strained to create a single-cell suspension. The cells were counted on a hemacytometer (Hausser Scientific) as the suspension was centrifuged at 1200 rpm for 5 minutes at 4 °C. The supernatant was dis-

carded and the pellet was resuspended in a buffer consisting of 0.5% bovine serum albumin (BSA; Sigma-Aldrich) and 2 mM ethylenediaminetetraacetic acid (EDTA; ThermoFisher) in PBS (PEB buffer) at a concentration of  $80 \mu\text{L}$  per  $10^7$  total cells.

Endothelial (CD31<sup>+</sup>) and hematopoietic (CD45<sup>+</sup>) cells were removed from the suspension. These cells were magnetically labelled by adding  $10 \mu\text{L}$  CD31 and CD45 antibody-conjugated microbeads (Miltenyi Biotec) per  $10^7$  total cells and incubating at  $4^\circ\text{C}$  for 15 minutes. Cells were washed in  $1 \text{ mL}$  PEB buffer per  $10^7$  cells, centrifuged at 1200 rpm for 5 minutes at  $4^\circ\text{C}$ , and resuspended in  $500 \mu\text{L}$  PEB buffer per  $10^8$  cells. The cells were then pipetted onto prepared LS columns (Miltenyi Biotec) fixed in a QuadroMACS separator (Miltenyi Biotec) at  $500 \mu\text{L}$  per column. After the cell suspension had flowed through the column, the columns were washed twice with  $3 \text{ mL}$  PEB buffer. The CD31<sup>−</sup>/CD45<sup>−</sup> flowthrough was collected, counted, and resuspended in  $90 \mu\text{L}$  PEB buffer per  $10^7$  total cells.

Epithelial cells expressing epithelial cell adhesion molecule (EpcAM<sup>+</sup>) cells were sorted and reserved for experiments. These cells were labelled and isolated in the same way using microbeads conjugated with an EpcAM antibody. EpcAM expression has been used to purify ATII cells, relative to ATI cells, since they tend to express higher levels of this marker.<sup>42</sup> EpcAM<sup>+</sup> cells were removed from the LS column by removing the column from the QuadroMACS separator, placing the column over a  $15 \text{ mL}$  conical tube, and quickly flowing  $5 \text{ mL}$  PEB buffer through the column twice. The isolated EpcAM<sup>+</sup> cells were then counted, centrifuged at 1200 rpm for 5 minutes at  $4^\circ\text{C}$ , and resuspended in complete medium (DME/F-12; Cytiva) with  $100 \text{ U mL}^{-1}$  penicillin,  $100 \text{ mg mL}^{-1}$  streptomycin, and  $2.5 \text{ mg mL}^{-1}$  amphotericin B (Life Technologies), supplemented with 10% fetal bovine serum (FBS; ThermoFisher). This procedure resulted in the isolation of approximately  $5 \times 10^5$  viable EpcAM<sup>+</sup> cells per mouse, of which approximately 83% were SFTPC<sup>+</sup> immediately post-isolation (Fig. S3†). The non-ATII population may have consisted of additional lung epithelial cell types included ATI and upper airway cells.

Primary murine fibroblasts were isolated from dual-transgenic reporter C57BL/6J mice following the same protocol. After the removal of CD31<sup>+</sup>/CD45<sup>+</sup> cells, alveolar fibroblasts expressing platelet derived growth factor receptor alpha (PDGFR $\alpha$ <sup>+</sup>) were labelled and isolated as described above.<sup>43</sup> The isolated PDGFR $\alpha$ <sup>+</sup> cells were then counted, centrifuged at 1200 rpm for 5 minutes at  $4^\circ\text{C}$ , and resuspended in complete growth media. This procedure resulted in the isolation of approximately  $4 \times 10^5$  viable PDGFR $\alpha$ <sup>+</sup> cells per mouse.

**Formation of 3D acinar structures.** The isolated ATII cells were collected, counted, and magnetically labeled to enable magnetic aggregation in 3D acinar structures. Cells were resuspended in complete media at  $2.5 \times 10^6$  cells per mL and NanoShuttle (Greiner Bio-One) was added at a concentration of  $250 \mu\text{L mL}^{-1}$  media, following the manufacturer's protocol. The mixture was mixed by pipetting up and down and centrifuged at 1200 rpm at  $4^\circ\text{C}$  for 5 minutes. The mixture was mixed and centrifuged two more times for a total of three cen-

trifugations. The magnetically labeled ATII cells were mixed with microspheres using an experimentally determined cell seeding density of 250 ATII cells per microsphere (Fig. S4†). Next, approximately 250 microspheres and  $6.25 \times 10^4$  ATII cells were aliquoted into an ultra-low adhesion 24-well plate. Complete media supplemented with 10% FBS was added to each well up to  $350 \mu\text{L}$  total volume and a 24-Well Levitating Drive (Greiner Bio-One) was placed over the plate. The plate was then incubated at  $37^\circ\text{C}$  for 72 hours on an orbital shaker plate to allow aggregation of the 3D acinar structures (Fig. S4†).

**Preparation of embedding hydrogels.** The 3D acinar structures were embedded in either a soft or stiff PEG-NB hydrogel to represent healthy or diseased lung tissue. The embedding hydrogel contained a  $10 \text{ kg mol}^{-1}$  PEG-NB backbone and a dithiol peptide crosslinker selected for degradation by MMP2 (KCGPQGIWGQCK; Genscript) to enable remodeling by embedded fibroblasts.<sup>44</sup> The weight percentages and crosslinker ratios of the embedding hydrogels were determined experimentally by using parallel plate rheology to identify two formulations with mimicking the elastic modulus ( $E$ ) of healthy (5.0 wt% PEG-NB,  $r = 0.7$ ,  $E = 2.7 \text{ kPa}$ ) and fibrotic (7.5 wt% PEG-NB,  $r = 0.8$ ,  $E = 18.1 \text{ kPa}$ ) lung tissue ( $N = 8$ ). A  $10 \text{ kg mol}^{-1}$  PEG-NB macromer was required to achieve this approximately 6-fold difference in modulus using the same polymer backbone. Embedding hydrogels were prepared by dissolving the  $10 \text{ kg mol}^{-1}$  PEG-NB backbone, MMP2-degradable crosslinker, and biologically active peptides (CGRGDS and CGYIGSR) individually in complete media supplemented with 10% FBS and sonicating for 10 minutes at  $40^\circ\text{C}$ . The PEG-NB was combined at the appropriate final weight percentage with the biologically active peptides, both at a 2 mM final concentration, and vortexed (Tube 1). The crosslinker was combined at the appropriate r-ratio with 15 mM TCEP and sonicated for 10 minutes at  $40^\circ\text{C}$  (Tube 2). LAP was added to Tube 1 at a final concentration of 4.5 mM and vortexed, and the entire contents of Tube 2 were added to Tube 1. The peptide sequences obtained commercially were guaranteed to be delivered with 95% purity. The small amount of residual acid in these peptides made it necessary to measure and adjust the pH of the prepared hydrogel precursor solution to provide a pH neutral environment for cells during embedding and thus improve viability. The solution was then measured using color bonded pH test papers (Cytiva) and neutralized with 3 M potassium hydroxide (Sigma-Aldrich) and 1 M hydrochloric acid. Freshly isolated primary murine fibroblasts were added to complete media supplemented with 10% FBS. This cell suspension was then added to the hydrogel stock solution for a final concentration of 60 000 cells per sample (6000 cells per  $\mu\text{L}$  stock solution) to bring the stock solution up to the desired final gel volume.

**Assembly of 3D lung models.** The magnetic levitating drive was removed and the 24-well plate containing the microspheres and ATII cells was placed on a 24-Well Holding Drive (Greiner Bio-One). The media was manually aspirated from each well and the 3D acinar structures were circled with a



hydrophobic pen. 10  $\mu\text{L}$  of the prepared embedding hydrogel and fibroblast solution was pipetted onto each structure using a positive displacement pipette. The samples were exposed to 365 nm UV light at 10  $\text{mW cm}^{-2}$  (Omnicure, Lumen Dynamics) for 5 minutes. The 3D lung models were then transferred to a new 24-well plate with complete media supplemented with 10% FBS and incubated at 37  $^{\circ}\text{C}$ . Samples embedded in soft embedding hydrogel were kept in Costar 24-well transwell inserts (Corning) to minimize exposure to mechanical forces during media changes.

### Characterization of 3D lung models

**Hydrogel characterization.** Evaluation of hydrogel mechanical properties was performed by parallel plate rheology. Briefly, hydrogel samples (height = 1 mm; diameter = 8 mm) were prepared according to the procedure described above and swelled overnight in PBS at room temperature. The samples were then trimmed as necessary and fitted onto a Discovery HR2 rheometer (TA Instruments) between an 8 mm diameter parallel plate geometry and a Peltier plate set to 37  $^{\circ}\text{C}$ . The geometry was lowered until 0.03 N axial force was applied. The gap distance was noted and decreased until the storage modulus measurement ( $G'$ ) plateaued. The percent compression at plateau of the specific hydrogel was used for each subsequent measurement for that sample type.<sup>45</sup> All samples were subjected to frequency oscillatory strain with a range of 0.1 to 100  $\text{rad s}^{-1}$  at 1% strain. The elastic modulus ( $E$ ) was calculated using rubber elasticity theory, assuming a Poisson's ratio of 0.5 for bulk measurements of the elastic hydrogel polymer network.<sup>46</sup>

**Hydrogel microsphere characterization.** Hydrogel microsphere emulsion polymerization conditions were determined experimentally to optimize microsphere diameter. Multiple stir speeds were tested across multiple emulsion times prior to UV exposure and the size distribution of the resulting microspheres containing the fluorescent label AlexaFluor 647 c2-maleimide (ThermoFisher) was analyzed on an upright epifluorescent microscope (BX-63; Olympus). Microsphere diameters were measured using ImageJ and a histogram was generated from each experimental condition. Individual microspheres were identified on ImageJ using the watershed function and subsequently analyzed. The resulting major axis measurement of each microsphere was taken to be the diameter. The condition resulting in spheres with a median diameter closest to 200  $\mu\text{m}$  (300 rpm, 30 seconds; median diameter =  $171 \pm 42 \mu\text{m}$ ) was chosen for the following experiments.

**Cellular viability.** Long-term viability of the primary murine ATII cells and fibroblasts co-cultured within both the healthy and fibrotic 3D lung models was confirmed with a live/dead staining assay (Millipore Sigma QIA76). 3D lung models were rinsed once with PBS and then incubated in a 1 : 1000 dilution each of Cyto-dye (green) and propidium iodide (red) for 40 minutes at 37  $^{\circ}\text{C}$ . Samples were rinsed in PBS and then placed in a solution of 10% FBS in PBS for immediate imaging on a 3i MARIANAS inverted spinning disk confocal micro-

scope. Three 50  $\mu\text{m}$  z-stacks were acquired per sample, with three samples per condition. Positive cells in each channel were quantified using Fiji (ImageJ) by producing a maximum projection of the z-stack, thresholding, and counting particles. Particle counting was performed on single channel images only, and an outline overlay used to manually confirm that the count was accurate to the original image. Data are presented as  $n = 5-7$  where each sample is the average of 3-6 images (minimum 200 cells counted per sample).

**Visualization of cellular distribution in 3D lung models.** Whole 3D lung models, containing primary murine epithelial cells and fibroblasts, were rinsed in PBS, fixed for 30 minutes in 4% paraformaldehyde (PFA; Electron Microscopy Sciences) in PBS, and permeabilized for 30 minutes in 0.5% TritonX-100 in PBS (Fisher). The samples were then blocked for 1 hour in 3% BSA in PBS before overnight incubation at 4  $^{\circ}\text{C}$  with rabbit anti-SFTPC (ThermoFisher PA5-71680, 1 : 25), hamster anti-Podoplanin (ThermoFisher MA5-18054, 1 : 100), and rat anti-Cytokeratin 8 (Developmental Studies Hybridoma Bank TROMA-I,<sup>47</sup> 1 : 25). Surfactant protein C (SFTPC) is a marker of ATII cells, while podoplanin (PDPN) and cytokeratin-8 (KRT8) are markers of ATI and transitional epithelial cells, respectively. Samples were washed three times with 0.1% Tween-20 (Fisher) in PBS, incubated for 1 hour at room temperature with AlexaFluor 488 goat anti-rat, AlexaFluor 647 goat anti-hamster, and AlexaFluor 555 goat anti-rabbit (ThermoFisher, 1 : 400), then again washed three times with 0.1% Tween-20 in PBS. Samples were stained with 5  $\mu\text{g mL}^{-1}$  Hoechst (Tocris) in PBS for 30 minutes, washed three times with PBS, and then imaged on an upright, epifluorescent microscope (Olympus, BX-63). For each sample, three 60  $\mu\text{m}$  z-stacks were acquired with the 10x objective. Image processing was performed by first running a Weiner deconvolution and generating a maximum projection before thresholding and counting particles in Fiji (ImageJ; minimum 400 cells counted per sample). Particle analysis was first performed on single channel images to quantify total positive cells and then on a color overlay to quantify double positive cells, the number of which was subtracted from the total to determine single positive cells. An outline view of each particle analysis was generated for manual comparison to the original image to ensure count accuracy.

**Cellular activation.** 3D lung models were generated using fibroblasts isolated from dual-reporter mice. These cells express GFP under the control of the collagen 1 alpha chain 1 (Col1a1) promoter and RFP under the control of the alpha smooth muscle actin ( $\alpha\text{SMA}$ ) promoter, allowing for visualization of myofibroblast activation using endogenous labels. Fibroblasts were cultured either alone or in co-culture with ATII cells and allowed to recover in complete media with 10% FBS for one week, after which they were cultured in low-serum activation media (complete media with 1% FBS) for an additional 1-2 weeks. At each time point, six samples per condition (soft and stiff embedding hydrogel, with and without ATII cells) were processed for imaging analysis. Whole samples were incubated with 5  $\mu\text{g mL}^{-1}$  Hoechst in PBS for 30 minutes

at 37 °C, washed once with PBS, and then kept in complete media during imaging on a 3i MARIANAS inverted spinning disk confocal microscope. Three 100  $\mu\text{m}$  z-stacks were acquired per sample and were quantified in Fiji by producing a maximum projection of each channel of the z-stack, thresholding, and counting particles (minimum 100 cells counted per sample). Particle analysis was first performed on single channel images to quantify total positive cells and then on a color overlay to quantify double positive cells, the number of which was subtracted from the total to determine single positive cells. An outline view of each particle analysis was generated in order to manually compare to the original image to ensure count accuracy. Data are presented as  $n = 6$  where each sample is the average of three images.

**RNA isolation and qPCR array.** RNA was isolated from the 3D lung models after 21 days of incubation. Three samples were pooled in RNase-free 1.5 mL microcentrifuge tubes and rinsed in sterile PBS for 5 minutes on a rocker. The PBS was then removed and the samples were flash-frozen by submerging the tubes in liquid nitrogen. Samples were manually homogenized with an RNase-free plastic pestle and by pipetting during the thawing process. Samples were then incubated in 500  $\mu\text{L}$  serum-free media with 2  $\text{mg mL}^{-1}$  collagenase at 37 °C for 10 minutes, or until the embedding hydrogels had visibly degraded. Next, 500  $\mu\text{L}$  TRIzol reagent (Life Technologies) was added to each tube and the samples were mixed by pipetting and incubated on ice for 5 minutes. 100  $\mu\text{L}$  1-bromo-3-chloropropane (BCP; Fisher Scientific) was then added to each sample. The samples were vortexed, incubated at room temperature for 10 minutes, then cooled on ice and centrifuged at 14 000g for 15 minutes. The clear layer of each sample was transferred to a new RNase-free 1.5 mL microcentrifuge tube with 500  $\mu\text{L}$  of isopropyl alcohol, vortexed, and incubated at room temperature for 10 minutes. The samples were cooled on ice and centrifuged at 14 000g for 10 minutes. The supernatant was discarded and 1 mL 70% ethanol (Decon Laboratories) was added. The samples were vortexed and centrifuged at 14 000g for 5 minutes. The supernatant was discarded and the samples were allowed to air dry. The dried pellets were resuspended in 16  $\mu\text{L}$  of RNase-free water (Qiagen). RNA quantity and purity were measured on a BioTek plate reader using a Take3 Micro-Volume Plate. Purity was assessed based on the ratio of absorbance readings taken at 260 nm and 280 nm ( $A_{260}/A_{280}$ ).

The isolated RNA was then analyzed using a mouse fibrosis specific RT<sup>2</sup> Profiler PCR Array (Qiagen), which measures the expression of 84 genes known to be involved in the progression of fibrosis. 40 U RNase inhibitor (Sigma-Aldrich) was added to the eluted RNA. cDNA was created from 3.6  $\mu\text{g}$  RNA using a Qiagen RT<sup>2</sup> First Strand Kit.

**Statistical analysis.** Viability experiments comparing soft *versus* stiff embedding hydrogel were assessed by two-tailed *t*-test at each timepoint. Activation experiments were analyzed by two-way analysis of variance (ANOVA) with Tukey's Test for multiple comparisons. Gene expression analysis was performed on the RT<sup>2</sup> Profiler PCR Array Data Analysis Webportal


(Qiagen). Normalized gene expression ( $2^{-\Delta\text{CT}}$ ) was calculated relative to the housekeeping gene B2M and genes with a fold regulation of at least two in any experimental group relative to the control were entered into a Gene Ontology Enrichment Analysis looking for enriched biological processes. The resulting networks were synthesized and summarized as general gene families and incorporated into the heatmap (Fig. 6). All gene outputs from the array are presented as relative expression in the supplement (Table S1†).

## Results & discussion

### 3D lung models recapitulate pulmonary micro-architecture and elastic modulus

We present a strategy for engineering 3D lung models using PEG-NB hydrogels that enables researchers to study crosstalk between epithelial cells and fibroblasts as well as cellular responses to changes in mechanical properties within precisely defined 3D geometries that recapitulate lung tissue. First, MMP3-degradable hydrogel microspheres were generated to serve as a template for arranging epithelial cells into geometries that mimic lung micro-architecture. PEG-NB macromers (40  $\text{kg mol}^{-1}$ ) were combined with an MMP3-degradable crosslinker, thiolated magnetic nanoparticles (MNPs) to enable magnetic aggregation into acinar structures, and peptide sequences from fibronectin (CGRGDS) and laminin (CGYIGSR) to promote cell attachment and survival, in a photoinitiated emulsion polymerization procedure (Fig. 1a). The same thiol-ene click chemistry incorporated a fluorescent label to allow visualization and measurement of the microspheres (Fig. 1b). A 40  $\text{kg mol}^{-1}$  PEG-NB macromer was selected to increase the average molecular weight between crosslinks in the resulting hydrogel networks and enhance degradation of microsphere templates when MMP3-degradable peptide sequences were cleaved by ATII cell-secreted enzymes. The peptide crosslinker used in the microsphere formulation was selected for degradation by MMP3 based on previous studies that showed MMP3 was expressed by ATII cells in human lungs,<sup>36</sup> and was further upregulated during IPF.<sup>33,34</sup> Microsphere templates were designed to degrade to form alveolar-like cyst structures at the center of the 3D model. Following emulsion polymerization, the resulting hydrogel microspheres were filtered with 100  $\mu\text{m}$  and 85  $\mu\text{m}$  filters to select a population that displayed sizes matching the average diameter of the human alveolus (median diameter =  $171 \pm 42.1 \mu\text{m}$ ; Fig. 1c).<sup>24</sup> Parallel plate rheology confirmed that the elastic modulus of these hydrogel microspheres ( $4.62 \pm 1.01 \text{ kPa}$ ; Fig. 1d) matched values reported for healthy lung tissue (2–5 kPa).<sup>22</sup>

To form higher-order acinar structures, hydrogel microspheres were coated with primary murine ATII cells (250 cells per microsphere) and aggregated under a magnetic field for three days, resulting in even distribution of ATII cells around tightly clustered microspheres (Fig. 2a). Each aggregate consisted of 250 microspheres which, after three days, were evenly coated by epithelial cells and formed a 3D structure approxi-




**Fig. 1** Emulsion polymerization produced hydrogel microspheres for templating alveolar micro-architecture. (A) An overview of the microsphere fabrication process detailing chemical components and emulsion parameters. Created with BioRender.com. (B) Representative fluorescent image of polymerized microspheres showed spherical geometry. Scale bar, 100  $\mu$ m. (C) Image analysis of microsphere diameter from fluorescent microscope images demonstrated that collecting 85–100  $\mu$ m filtrate yielded physiologically relevant microspheres sizes (median diameter =  $171 \pm 42$   $\mu$ m;  $N = 4$ ). (D) Parallel plate rheology confirmed that microsphere stiffness was within the range of healthy lung tissue ( $E = 4.62 \pm 1.01$  kPa;  $N = 8$ ).

mately 1 mm to 1.5 mm in diameter (Fig. S4†). This size allowed for analysis of a higher-order geometry while still being small enough that cells remained viable at the center of the aggregate. These 3D acinar structures were then embedded in another PEG-NB hydrogel laden with primary murine fibroblasts at a 1:1 ratio to ATII cells to create 3D lung models (Fig. 2a and Fig. S4†). Estimates of cell numbers in the lung suggest that, while epithelial cells take up a high proportion of lung tissue due to their large size, there are numerous quiescent fibroblasts present in healthy lung,<sup>48</sup> making the 1:1 ratio physiologically relevant.

The embedding hydrogel was comprised of the PEG-NB macromer crosslinked with an MMP2-degradable peptide sequence, along with the same fibronectin and laminin-derived adhesion peptides. For embedding hydrogels, a 10 kg mol<sup>-1</sup> PEG-NB macromer was used to facilitate the formation of both soft and stiff hydrogels with a large enough difference in elastic modulus to recapitulate the dramatic tissue stiffening observed during fibrosis using the same polymer backbone. The peptide crosslinker was designed to allow environ-

mental remodeling by fibroblasts, which express MMP2 basally, and increase that expression during IPF.<sup>44,49</sup> Importantly both MMP2- and MMP3-degradable peptide sequences were tailored for high rates of degradation by those specific enzymes, which are produced by the cells in proximity to each hydrogel formulation, fibroblasts and ATII cells, respectively. However, the MMP2-degradable sequence can also be degraded by MMP1, MMP3, MMP8, and MMP9 and the MMP3-degradable sequence may also be degraded by MMP-7.<sup>32</sup>

The ability of fibroblasts to interact with the extracellular microenvironment and spread over time is critical for activation to the myofibroblast phenotype within fibrous synthetic composite hydrogels<sup>50</sup> (Fig. 2b). The formulation of the embedding hydrogel was tailored to produce either a soft embedding hydrogel ( $E = 2.7 \pm 0.31$  kPa) to mimic healthy lung ( $E = 2$ –5 kPa (ref. 22)), or a stiff embedding hydrogel ( $E = 18.1 \pm 1.34$  kPa) to mimic fibrotic lung ( $E = 10$ –30 kPa;<sup>22</sup> Fig. 2c) as measured by parallel plate rheology. The result of this microsphere aggregation and embedding procedure was the pro-



**Fig. 2** Formation of 3D acinar structures. (A) Overview of the 3D acinar structure fabrication process. Created with BioRender.com. (B) Confocal image showing ATI cells (green) dispersed across the surface of aggregated microspheres (red) in three dimensions. Scale bar, 50  $\mu\text{m}$ . (C) Schematic depicting the embedding hydrogel formulation and polymerization process. These materials were crosslinked with an MMP2-degradable dithiol crosslinker to enable fibroblast-mediated matrix remodeling. (D) Parallel plate rheology confirmed that embedding hydrogel formulations recapitulated the elastic modulus of healthy ( $E = 2.7 \pm 0.31$  kPa) or fibrotic lung tissue ( $E = 18.1 \pm 1.34$  kPa).  $N = 8$ .

duction of a 3D lung model in which primary murine ATI cells formed alveoli-like structures while surrounded by an environment that reproduced the mechanical microenvironment and cellular landscape of pulmonary interstitial tissue.

To create hollow alveoli-like structures, hydrogel microsphere templates were designed to be degradable by ATIs, which produce MMP3.<sup>51</sup> Microsphere degradation over time was assessed by incorporating methacrylated rhodamine in the hydrogel formulation and quantifying the loss of fluorescence intensity. Microsphere degradation was measured in response to the addition of exogenous enzyme (Fig. S5†) and in response to cell-secreted enzymes within 3D lung models over the three-week experimental timeframe was measured (Fig. S6†). The addition of 0.125 to 0.25  $\text{mg mL}^{-1}$  of elastase completely degraded individual microspheres within 20 minutes (Fig. S5†). Within 3D lung models, microspheres showed partial, but not complete degradation with approximately 60% of the original fluorescence intensity remaining at three weeks (Fig. S6†). Most of this degradation can be attributed to enzymatic degradation of the MMP3-cleavable peptide crosslinker. While no visual degradation of embedding hydrogels occurred, a small amount of hydrolytic degradation may also be expected to occur over the course of a multi-week experiment in both the hydrogel microspheres and embedding hydrogels, as previously reported for ester bond-linked PEG-NB.<sup>52,53</sup> Future long-term studies could benefit from even

more stable PEG derivatives, such as PEG alpha-methacrylate, which our group has reported to be hydrolytically stable for up to 60 days under cell culture conditions.<sup>54</sup>

Previous studies have reported culturing lung cells on hydrogel microspheres to model alveolar micro-architecture. Lewis *et al.*, fabricated photodegradable PEG-based hydrogel microspheres (mean diameter =  $120 \pm 70$   $\mu\text{m}$ ) and coated these templates with epithelial cells. Single microspheres were embedded in a stiff hydrogel ( $E \sim 20$  kPa) and exposure to ultraviolet light degraded away the microsphere templates, creating a cyst that mimicked the structure of a single alveolus.<sup>24</sup> By encapsulating a fibroblast cell line in the embedding hydrogel, they subsequently demonstrated that A549 cancer cells could activate fibroblasts in this 3D model. Our model relies on similar PEG-based microspheres but aggregated into larger acinar structures and with the incorporation of primary lung cells, rather than cell lines. Similarly, Wilkinson *et al.*, used a custom bioreactor to aggregate human fetal lung fibroblasts around collagen-functionalized alginate microspheres (diameter =  $161 \pm 80$   $\mu\text{m}$ ) to create mesenchymal lung organoids that formed an extended tissue network more fully reproducing 3D lung micro-architecture and allowing for the study of transforming growth factor- $\beta$  (TGF- $\beta$ ) mediated fibroblast activation in the presence of additional cell types.<sup>26</sup> In contrast to the static natural materials used to form these hydrogel microspheres, our PEG-based hydrogels are highly customizable, allowing us to also assess cellular responses to




changing environmental mechanics. In this way, we combined the tunability of PEG hydrogels for microsphere fabrication with a magnetic aggregation step to create a novel 3D model of higher-order lung structure. This model contains primary epithelial cells that can be embedded with fibroblasts inside hydrogels to mimic either healthy or diseased lung parenchyma.

### Cells maintain viability and undergo differentiation within 3D lung models

To assess the long-term viability of cells within 3D lung models, constructs were maintained in culture for up to three weeks and the percent of live cells was measured weekly *via* live/dead nuclear staining. Viability of epithelial cells vs fibro-

blasts was differentiated by the region of the aggregate imaged, since the central, microsphere-associated regions were seeded predominantly with epithelial cells, while the peripheral embedding hydrogel contained mostly fibroblasts. With respect to epithelial cells, viability was largely stable, showing slightly lower initial values the day after embedding (week 0), ( $74.3 \pm 18.8\%$  for soft and  $56.6 \pm 27.1\%$  for stiff). After one week in culture the viability had recovered and then maintained at high levels between 72.4% and 91.9% for both embedding hydrogel conditions out to three weeks (Fig. 3a). Critically, cells in the center of aggregates maintained high viability across all timepoints, indicating that nutrient and gas diffusion proceeds freely throughout the 3D structure (Fig. 3b). For fibroblasts, initial viability at week 0 was even lower ( $69.2 \pm$



**Fig. 3** 3D lung models supported cell viability of both (A) epithelial cells (imaged in the central area containing microsphere templates) and (B) fibroblasts (imaged in the peripheral embedding hydrogel). Data are reported as percent live cells out to at least 3 weeks post-embedding in both hydrogel conditions. Representative confocal images (50  $\mu\text{m}$  z-stacks displayed as a maximum intensity projection) showed even distribution of live (green) (C) epithelial cells at the center of 3D lung models with preserved pulmonary architecture and (D) fibroblasts evenly distributed through the embedding hydrogel with relatively low numbers of dead (red) cells ( $n = 5-7$ ). Scale bar, 100  $\mu\text{m}$ .

18.4% for soft and  $45.2 \pm 11.2\%$  for stiff), likely due to stress imposed on the cells by the embedding process. Still, in subsequent weeks viability improved notably, with values in both conditions between 81.6% and 90.0%. The total number of epithelial cells (Fig. S7A†) and fibroblasts (Fig. S7B†) per area were counted from live/dead images. There were no statistical differences measured in cell number over time in any group (ANOVA). These changes in viability were likely due to clearance of dead cells, since overall numbers of epithelial cells remained largely stable, while the numbers of fibroblasts showed a trend towards decrease in the first two weeks before plateauing. Interestingly, the decrease was not as steep in the stiff hydrogel conditions, although initial viability was lower. This result could suggest that a moderate amount of fibroblast proliferation was occurring in stiff hydrogels to partially maintain the overall population (Fig. S7†).


*In situ*, ATII cells possess the ability to differentiate into ATI cells, changing their morphology, function, and gene expression in response to epithelial injury. This natural tendency for ATII cells to drift toward an ATI phenotype has also been observed *in vitro* in 3D hydrogel models.<sup>24</sup> It is well documented that the lung epithelium is heavily involved in the regulation of pulmonary fibrosis. Healthy epithelium can secrete antifibrotic factors such as prostaglandin-E2 (PGE2) and bone morphogenetic protein-4 (BMP4) that restrain fibroblast activation and help maintain healthy lung morphology.<sup>21,55</sup> Conversely, damaged epithelium secretes pro-fibrotic factors, including TGF- $\beta$ , PDGF, and CTGF, that induce myofibroblast activation and fibrotic progression.<sup>6,7</sup> Epithelial damage also induces differentiation of ATII cells into ATI cells as part of normal, healthy re-epithelialization. During fibrosis, a population of transitional ATII cells persists and contributes to a positive feedback loop of fibrotic progression.<sup>5</sup> We assessed epithelial cell identity within aggregates over time by immunofluorescence staining for an ATII cell marker, SFTPC, a transitional ATII-ATI marker, KRT8, and an ATI cell marker, PDPN (Fig. 4a). While the majority of seeded epithelial cells (approximately 85%) initially expressed SFTPC, over the course of three weeks a population of PDPN+ ATI cells emerged, indicating differentiation over time. Interestingly, at the initial time point, 10–15% of seeded cells were already expressing the transitional marker KRT8, and this population expanded up to 20–25% by week 3 (Fig. 4b). These shifts in epithelial cell population mimic the sustained transitional cell phenotype observed in pulmonary fibrosis, where transitional ATII cells are known to emerge in response to epithelial injury and share pro-fibrotic hallmarks with various other pathological states.<sup>56</sup> These transitional cells have been found to display phenotypes similar to epithelial–mesenchymal transition<sup>57</sup> and cellular senescence,<sup>58</sup> particularly in terms of increased TGF- $\beta$  signaling. The primary murine ATII cells included in this model started to undergo this transition, resulting in a mixed population of ATII and ATI cells alongside cells that are present in this transitional pathologic state. Critically, these aggregates all contained PDGFR $\alpha$ -expressing fibroblasts, an alveolar fibroblast population that has been noted to promote both ATII cell

self-renewal and differentiation to ATI cells.<sup>43</sup> While the transitional epithelial cell phenotype has, to date, largely been observed *in vivo*, emerging *in vitro* data suggests that fibroblasts also play a critical role in initiating and maintaining this unique epithelial cell state.<sup>59</sup> Taken together, these data demonstrate the capacity of this *in vitro* co-culture model to recapitulate the cellular heterogeneity that is a hallmark of fibrosis *in vivo*.


### Presence of ATII cells promotes fibroblast activation in stiff microenvironments

Fibroblasts are the central drivers of fibrotic progression because these cells synthesize and remodel fibrotic ECM in a positive feedback loop of cellular activation and tissue stiffening.<sup>60</sup> The importance of epithelial–mesenchymal crosstalk to this fibrotic activation has been observed *in vivo* but is still lacking within *in vitro* models. To interrogate the effects of both microenvironmental stiffness and epithelial cell interactions on fibroblast activation in the context of IPF, fibroblasts were isolated from dual-transgenic reporter mice. These reporter cells express red fluorescent protein (RFP) under the control of the alpha smooth muscle actin ( $\alpha$ SMA) promoter and green fluorescent protein (GFP) under the control of the collagen 1 alpha chain 1 (Col1a1) promoter, offering a visual indication of cellular activation and transition toward the active myofibroblast phenotype.<sup>61</sup> Fibroblasts were cultured in four conditions: around 3D acinar structures, with or without epithelial cells incorporated, and within either soft or stiff embedding hydrogels, with activation assessed at weeks 0, 2, and 3 in culture. At the week 0 timepoint, just 24 hours post-encapsulation, fibroblasts in all conditions were highly disperse and showed rounded morphology with minimal expression of either  $\alpha$ SMA or Col1a1. Over time, fibroblasts were able to sense and react to the hydrogel environment and displayed increased spreading and expression of pro-fibrotic markers. Fibroblasts cultured with epithelial cells in a stiff extracellular environment showed significantly higher expression of  $\alpha$ SMA and Col1a1 after 3 weeks compared to co-culture in a soft extracellular environment or fibroblasts in monoculture (Fig. 5A). In particular, the presence of epithelial cells caused an early expansion of  $\alpha$ SMA+ myofibroblasts by week 2 (Fig. 5B). By week 3, the dual stimulus of epithelial cell presence and microenvironmental stiffness dramatically increased the population of activated fibroblasts, as demonstrated both by activation marker expression and enhanced cell spreading (Fig. 5C). These results supported the hypothesis that the combination of mechanical and cellular cues is critical to promoting a fibrotic response, more so than either mechanical or cellular cues alone.

Prior studies have demonstrated fibroblast activation in response to mechanical cues. Fibroblasts cultured on a 2D hydrogel with an established stiffness gradient exhibited increased spreading, proliferation, and migration as the elastic modulus of the substratum increased.<sup>62</sup> The relationship between environmental stiffness and fibroblast activation is more complex in 3D models, where factors such as the density



**Fig. 4** Epithelial cell identity shifted over time. (A) Representative fluorescent images of immunostaining of ATII (SFTPC), ATI (PDPN), and transitional (KRT8) markers in 3D lung models containing primary murine fibroblasts. (B) Image analysis of the epithelial cell population showed the majority of the ATII cell population retained that identity, with some ATII cells transitioning to an ATI or ATII-ATI transitional phenotype at 3 weeks post-embedding ( $n = 3$ ). Scale bar, 50  $\mu\text{m}$ .



**Fig. 5** Fibroblasts activated in response to stiffness and epithelial cell presence. (A) Fibroblast activation assessed up 3 weeks post-embedding revealed that fibroblast-epithelial cell co-culture and a stiff extracellular environment synergistically promoted fibroblast activation as measured by the percentage of  $\alpha$ SMA and/or Col1a1 expressing reporter fibroblasts in culture ( $n = 6$ ). (B) Within the activated cell population, the proportion of  $\alpha$ SMA + myofibroblasts increased over time in all conditions, but increased more quickly in co-culture conditions, suggesting that the presence of epithelial cells provokes a more rapid fibrotic response than mechanical cues alone ( $n = 6$ ). (C) Representative confocal images (maximum intensity projection of 100  $\mu$ m z-stacks) showed dual reporter fibroblasts within 3D lung models increased expression of activation reporters  $\alpha$ SMA and Col1a1 in co-culture within a stiff extracellular environment, particularly at three weeks. Scale bar, 50  $\mu$ m.

or deformability of the surrounding environment also play a role.<sup>50</sup> Prior studies of morphology of cells encapsulated in 3D hydrogels have suggested that over short-term culture<sup>63</sup> or in non-degradable hydrogels,<sup>64</sup> increased stiffness, *i.e.* network density, inhibits fibroblast spreading. In systems with sufficient porosity and/or degradability, and thus enough physical space for fibroblasts to spread, increased stiffness enhanced spreading.<sup>65</sup> In our enzymatically degradable 3D

hydrogel model, we demonstrated that increased microenvironmental stiffness alone could increase fibroblast activation, but that epithelial cells also played a synergistic role in this activation (Fig. 5a). Cellular crosstalk between fibroblasts and epithelial cells has been studied in numerous ways. Studies that have used conditioned media<sup>56</sup> or trans-well co-culture<sup>66</sup> to demonstrate the reciprocal crosstalk between damaged epithelium and activated fibroblasts have implicated key signaling




pathways in the development of IPF, but still rely on 2D cell culture, often on substrates with non-physiologically mechanical properties, resulting in abnormally high fibroblast activation. In an organoid co-culture model, healthy epithelium inhibited the activation of fibroblasts through BMP signaling, even in the face of fibrotic stimulation with exogenous TGF- $\beta$ . Interestingly, this mitigated activation in the presence of TGF- $\beta$  was only observed in 3D culture, not 2D. These data support the concept that lung epithelium can play a critical regulatory role in the development of fibrosis and also highlight the power of studying cellular behavior in geometrically relevant 3D culture systems.<sup>21</sup> Here, fibroblasts and epithelial cells were co-cultured in a micropatterned 3D environment, and the presence of epithelial cells enhanced fibroblast activation. Critically, these results, along with immunostaining, suggested that the epithelial cells are not recapitulating healthy epithelium, but are reproducing aspects of fibrotic epithelium, with an injury response resulting in differentiation of ATII cells to ATI cells and the persistence of a transitional cell population (Fig. 4b). This mixed epithelial cell population, in concert with increased microenvironmental stiffness, results in a robust model of pathological fibroblast activation, highlighting the importance of models that allow researchers to control and study both cell-matrix and cell-cell interactions.

#### Co-culture in stiff PEG-NB microenvironments promotes upregulation of profibrotic genes

qRT-PCR analysis of 84 genes known to be involved in the progression of fibrosis was performed to further assess fibroblast activation and the fibrotic phenotype of cells within 3D lung models featuring different mechanical properties. Results revealed differences in the expression of several gene networks in response to environmental stiffness and the presence of epithelial cells (Fig. 6). In fibroblast-only cultures, a stiff microenvironment induced upregulation of genes involved in ECM remodeling and integrin signaling, suggesting that the cells sense this external stimulus and respond by expressing factors that would facilitate interactions with the extracellular environment. Interestingly, prior studies in 3D cultures of fibroblasts aimed at the study of IPF demonstrated that interactions with the extracellular microenvironment were critical to the activation of myofibroblasts. Matera *et al.*, showed that fibroblasts encapsulated within a cell-degradable hydrogel acquired a myofibroblast phenotype in response to TGF- $\beta$  stimulation, but this effect was abrogated by treatment with an MMP inhibitor, indicating that the ability of fibroblasts to remodel their surrounding environment is critical to their activation.<sup>50</sup> In another model using decellularized slices of lung tissue as a 3D scaffold for cell culture, Booth *et al.*, demonstrated that ECM derived from fibrotic lung was sufficient to activate myofibroblasts, even in the absence of overall differences in TGF- $\beta$  signaling.<sup>67</sup> Both these data and ours highlight the critical role that cell-matrix interactions have in fibroblast activation.

Relative to fibroblast-only culture in soft microenvironments, co-culture with epithelial cells resulted in increased expression of genes related to TGF- $\beta$  signaling and cellular pro-



**Fig. 6** Fibrotic gene network analysis in 3D lung models. Expression of 84 fibrosis-associated genes was assessed using a Qiagen RT<sup>2</sup> Profiler PCR array. A subset of genes with a fold change greater than two in at least one condition relative to the soft, fibroblast-only condition is displayed. Within each gene, expression relative to the housekeeper ( $2^{-\Delta CT}$ ) was normalized across the four groups as a percent of maximum expression. This analysis revealed coordinated regulation of functionally related genes based on cellular co-culture and microenvironmental stiffness. Specifically, stiffness tended to promote the expression of genes related to cell-matrix interactions, while presence of epithelial cells resulted in enhanced expression of growth factors, pro-proliferative transcription factors, and TGF- $\beta$  signaling pathway members ( $n = 3$ ).

liferation. Although this system did not differentiate whether these genes were being produced by fibroblasts or the epithelial cells, it is suggestive of the creation of a pro-proliferative and pro-activation environment as the result of co-culture. Similarly, Suezawa *et al.*, treated organoids containing both stem-cell derived alveolar epithelial cells and primary fibroblasts with bleomycin, resulting in fibrotic gene expression and functional phenotypes that could not be recapitulated in monocultures of either cell types.<sup>27</sup> These results are in agreement with our own, even though our model did not require the addition of an exogenous pro-fibrotic treatment like bleomycin. Interestingly, the combined condition of co-culture in a stiff microenvironment showed a unique pattern of upregulation of genes across these groupings of cell-ECM and cell-cell interactions. Some of these unique changes may have been a result of direct interactions of epithelial cells with the altered environment. Kim *et al.*, demonstrated that biochemical differences in the ECM impacted the differentiation of epithelial cells, in that alveolar epithelial cells provided with exogenous

TGF- $\beta$  and cultured on fibronectin showed acquisition of epithelial-to-mesenchymal transition markers while those cultured on Matrigel, a different combination of matrix proteins, did not.<sup>57</sup> In our model, we provided epithelial cells with different mechanical inputs, which may also alter injury and stress responses.<sup>68</sup> Protein levels of TGF $\beta$  were assessed within soft and stiff co-culture hydrogels, revealing a trend towards increased TGF $\beta$  within stiff hydrogels (Fig. S8†). In contrast, TGF $\beta$  trended towards being higher in soft hydrogel constructs at the RNA level (Fig. 6). These results suggested that protein-level regulation of signaling pathways was contributing to enhanced fibroblast activation (Fig. 5). This could be true not only for TGF $\beta$  signaling, but also any other growth factors which gene expression data suggested to be of interest. There was likely a complex interplay between fibroblasts, epithelial cells, and the microenvironment that contributed to the unique gene expression patterns observed in this 3D co-culture model which could not be recapitulated by more reductionist systems.

One evident shortcoming of this reductionist model comes from the fact that most of the conditions tested displayed down-regulation of inflammation-related genes, which play a critical role in the maintenance and injury response phenotypes of alveolar epithelial cells.<sup>69</sup> Incorporation of different fibroblast subsets<sup>43</sup> and/or inflammatory cells into future 3D lung models could better recapitulate this aspect of fibrotic disease. Still, the findings presented here point to the value of this model in studying both cellular crosstalk between pulmonary fibroblasts and epithelial cells, as well as fibrotic matrix remodeling in a 3D culture model that provides a more relevant and impactful platform for the *in vitro* study of fibrotic disease.

## Conclusion

A significant need exists for improved *in vitro* models of IPF that take into account the variety of factors that contribute to fibrogenesis. Here, we demonstrate the fabrication and validation of a novel *in vitro* model of IPF using mechanically tunable hydrogels polymerized in physiologically relevant alveolar geometries. Magnetically aggregating these hydrogel microspheres into a 3D acinar structure created a more geometrically accurate distal lung model than has previously been established. Incorporating a fibroblast-epithelial cell co-culture along with control over extracellular mechanical cues into this 3D lung model enabled the study of multiple profibrotic factors working in concert with one another, creating a more complete *in vitro* distal lung model than is currently available. This model accurately reproduced the geometric and mechanical properties of native lung tissue and supported cell viability out to at least 3 weeks. Interrogation of the epithelial cells in this model found evidence of ATII cell differentiation into ATI cells, with a persistent population of transitional cells, as has been observed in fibrosis *in vivo*. Given that significant proliferation of epithelial cells was not observed over the course of three weeks, another phenotype captured by this model could potentially be epithelial cell senescence. Senescence markers

have been observed in pro-fibrotic transitional epithelial cells,<sup>5,70</sup> and are also implicated in other chronic lung diseases,<sup>71</sup> making this an interesting future direction for studies using this model. The fibroblasts in this model, conversely, displayed significant increases in activation and unique changes to gene expression patterns in response to the presence of epithelial cells and mechanical signals from the extracellular environment, suggesting that the combination of cellular interactions and mechanical cues generated a more profound fibrotic response than either factor alone. The initial success of this model also points toward future improvements that could increase its relevance in the study of human disease. Epidemiologically, men have higher incidence of IPF than women,<sup>72</sup> so while in this study male and female cells were pooled to reduce biological variability, future studies could be designed to analyze sex-differences in IPF pathogenesis. In terms of cell biology, in addition to fibroblasts and epithelial cells, inflammatory and/or endothelial cells could be added to the model to recapitulate the facets of IPF mediated by these cell types. From a biomaterials perspective, there is also considerable potential in the tunability of the hydrogel matrices. Future studies could alter the biochemical environment present in this model by incorporating additional peptide sequences or even ECM-derived protein components which might further influence fibroblast activation. Here, we have built and validated 3D models of healthy and fibrotic lung tissue using murine cells. Future studies will incorporate human cells to improve translational investigation of IPF signaling and/or responses to putative therapeutics. Overall, these findings demonstrated that hydrogel-based 3D lung models can serve as a powerful *in vitro* tools for integrating the multitude of complex processes that underlie the progression of fibrotic disease.

## Data availability

The raw and processed data required to reproduce these findings are available here: Caracena, Thomas; Blomberg, Rachel; Hewawasam, Rukshika; Riches, David; Magin, Chelsea; Fry, Zoe (2022), "Alveolar epithelial cells and microenvironmental stiffness synergistically drive fibroblast activation in three-dimensional lung models", Mendeley Data, V2, doi: <https://doi.org/10.17632/58k4dh2prp.2>

## Author contributions

Thomas Caracena: methodology, validation, investigation, writing – original draft. Rachel Blomberg: formal analysis, investigation, writing – original draft, supervision. Rukshika S. Hewawasam: validation, resources. Zoe E. Fry: formal analysis, investigation. David W. H. Riches: supervision, writing – review & editing. Chelsea M. Magin: conceptualization, methodology, writing – original draft, visualization, supervision, funding acquisition.

## Conflicts of interest

Chelsea Magin reports a relationship with Vanderbilt University that includes: speaking and lecture fees. Chelsea Magin has patent #PCT/US2019/012722 pending to University of Colorado.

## Acknowledgements

The authors would like to thank Dr Nicole J. Darling for assistance with drawing schematics in Fig. 1 and 2. TROMA-I anti-cytokeratin 8 antibody was developed by Brulet, P./Kemler, R. and obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242. This work was supported by funding from the American Thoracic Society Research Foundation Program (CMM), the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) under awards R01 HL153096 (CMM, TC, RB, and DWHR) and T32 HL 07085 (RB); the National Cancer Institute of the NIH under award R21 CA252172 (CMM and RB); the National Science Foundation under award 1941401 (CMM and RH); the Department of the Army under award W81XWH-20-1-0037 (CMM).

## References

- 1 R. L. C. HR and J. MG, *Lancet*, 2017, **389**(10082), 1941–1952.
- 2 H. Taniguchi, M. Ebina, Y. Kondoh, T. Ogura, A. Azuma, M. Suga, Y. Taguchi, H. Takahashi, K. Nakata, A. Sato, M. Takeuchi, G. Raghu, S. Kudoh and T. Nukiwa, The Pirfenidone Clinical Study Group in Japan, *Eur. Respir. J.*, 2010, **35**, 821.
- 3 L. Richeldi, R. M. du Bois, G. Raghu, A. Azuma, K. K. Brown, U. Costabel, V. Cottin, K. R. Flaherty, D. M. Hansell, Y. Inoue, D. S. Kim, M. Kolb, A. G. Nicholson, P. W. Noble, M. Selman, H. Taniguchi, M. Brun, F. Le Maulf, M. Girard, S. Stowasser, R. Schlenker-Herceg, B. Disse and H. R. Collard, *N. Engl. J. Med.*, 2014, **370**, 2071–2082.
- 4 J. P. Finnerty, A. Ponnuswamy, P. Dutta, A. Abdelaziz and H. Kamil, *BMC Pulm. Med.*, 2021, **21**, 411.
- 5 M. Strunz, L. M. Simon, M. Ansari, J. J. Kathiriya, I. Angelidis, C. H. Mayr, G. Tsidiridis, M. Lange, L. F. Mattner, M. Yee, P. Ogar, A. Sengupta, I. Kukhtevich, R. Schneider, Z. Zhao, C. Voss, T. Stoeger, J. H. L. Neumann, A. Hilgendorff, J. Behr, M. O'Reilly, M. Lehmann, G. Burgstaller, M. Königshoff, H. A. Chapman, F. J. Theis and H. B. Schiller, *Nat. Commun.*, 2020, **11**, 1–20.
- 6 M. Selman and A. Pardo, *Respir. Res.*, 2002, **3**, 3–3.
- 7 M. Selman and A. Pardo, *Proc. Am. Thorac. Soc.*, 2006, **3**, 364–372.
- 8 M. Korfei, S. Schmitt, C. Ruppert, I. Henneke, P. Markart, B. Loeh, P. Mahavadi, M. Wygrecka, W. Klepetko, L. Fink, P. Bonniaud, K. T. Preissner, G. Lochnit, L. Schaefer, W. Seeger and A. Guenther, *J. Proteome Res.*, 2011, **10**, 2185–2205.
- 9 M. W. Parker, D. Rossi, M. Peterson, K. Smith, K. Sikström, E. S. White, J. E. Connett, C. A. Henke, O. Larsson and P. B. Bitterman, *J. Clin. Invest.*, 2014, **124**, 1622–1635.
- 10 J. K. Burgess, T. Mauad, G. Tjin, J. C. Karlsson and G. Westergren-Thorsson, *J. Pathol.*, 2016, **240**, 397–409.
- 11 F. Liu, J. D. Mih, B. S. Shea, A. T. Kho, A. S. Sharif, A. M. Tager and D. J. Tschumperlin, *J. Cell Biol.*, 2010, **190**, 693–706.
- 12 A. C. Brown, V. F. Fiore, T. A. Sulchek and T. H. Barker, *J. Pathol.*, 2013, **229**, 25–35.
- 13 E. S. White, *Ann. Am. Thorac. Soc.*, 2015, **12**, S30–S33.
- 14 B. Hinz, *Proc. Am. Thorac. Soc.*, 2012, **9**, 137–147.
- 15 Y. Kim, M. C. Kugler, Y. Wei, K. K. Kim, X. Li, A. N. Brumwell and H. A. Chapman, *J. Cell Biol.*, 2009, **184**, 309–322.
- 16 B. Moore, W. E. Lawson, T. D. Oury, T. H. Sisson, K. Raghavendran and C. M. Hogaboam, *Am. J. Respir. Cell Mol. Biol.*, 2013, **49**, 167–179.
- 17 Z. Yan, Z. kui and Z. Ping, *Autoimmun. Rev.*, 2014, **13**, 1020–1025.
- 18 A. Camelo, R. Dunmore, M. A. Sleeman and D. L. Clarke, *Front. Pharmacol.*, 2013, **4**, 173.
- 19 T. E. King, A. Pardo and M. Selman, *Lancet*, 2011, **378**, 1949–1961.
- 20 A. Betensley, R. Sharif and D. Karamichos, *J. Clin. Med.*, 2016, **6**, 2.
- 21 Q. Tan, X. Y. Ma, W. Liu, J. A. Meridew, D. L. Jones, A. J. Haak, D. Sicard, G. Ligresti and D. J. Tschumperlin, *Am. J. Respir. Cell Mol. Biol.*, 2019, **61**, 607–619.
- 22 R. H. J. de Hilster, P. K. Sharma, M. R. Jonker, E. S. White, E. A. Gercama, M. Roobeek, W. Timens, M. C. Harmsen, M. N. Hylkema and J. K. Burgess, *Am. J. Physiol.*, 2020, **318**, L698–L704.
- 23 M. Nizamoglu, R. H. J. de Hilster, F. Zhao, P. K. Sharma, T. Borghuis, M. C. Harmsen and J. K. Burgess, *Acta Biomater.*, 2022, **147**, 50–62.
- 24 K. J. R. Lewis, M. W. Tibbitt, Y. Zhao, K. Branchfield, X. Sun, V. Balasubramaniam and K. S. Anseth, *Biomater. Sci.*, 2015, **3**, 821–832.
- 25 K. J. R. Lewis, J. K. Hall, E. A. Kiyotake, T. Christensen, V. Balasubramaniam and K. S. Anseth, *Biomaterials*, 2018, **155**, 124–134.
- 26 D. C. Wilkinson, J. A. Alva-Ornelas, J. M. S. Sucre, P. Vijayaraj, A. Durra, W. Richardson, S. J. Jonas, M. K. Paul, S. Karumbayaram, B. Dunn and B. N. Gomperts, *Stem Cells Transl. Med.*, 2017, **6**, 622–633.
- 27 T. Suezawa, S. Kanagaki, K. Moriguchi, A. Masui, K. Nakao, M. Toyomoto, K. Tamai, R. Mikawa, T. Hirai, K. Murakami, M. Hagiwara and S. Gotoh, *Stem Cell Rep.*, 2021, **16**, 2973–2987.
- 28 Q. Tan, K. M. Choi, D. Sicard and D. J. Tschumperlin, *Biomaterials*, 2017, **113**, 118–132.

- 29 J. Herrera, C. A. Henke and P. B. Bitterman, *J. Clin. Invest.*, 2018, **128**, 45–53.
- 30 M. Ochs, J. R. Nyengaard, A. Jung, L. Knudsen, M. Voigt, T. Wahlers, J. Richter and H. J. G. Gundersen, *Am. J. Respir. Crit. Care Med.*, 2004, **169**, 120–124.
- 31 B. D. Fairbanks, M. P. Schwartz, A. E. Halevi, C. R. Nuttelman, C. N. Bowman and K. S. Anseth, *Adv. Mater.*, 2009, **21**, 5005–5010.
- 32 J. Patterson and J. A. Hubbell, *Biomaterials*, 2010, **31**, 7836–7845.
- 33 C. M. Yamashita, L. Dolgonos, R. L. Zemans, S. K. Young, J. Robertson, N. Briones, T. Suzuki, M. N. Campbell, J. Gauldie, D. C. Radisky, D. W. H. Riches, G. Yu, N. Kaminski, C. A. G. McCulloch and G. P. Downey, *Am. J. Pathol.*, 2011, **179**, 1733–1745.
- 34 V. J. Craig, L. Zhang, J. S. Hagood and C. A. Owen, *Am. J. Respir. Cell Mol. Biol.*, 2015, **53**, 585–600.
- 35 A. S. Caldwell, G. T. Campbell, K. M. T. Shekiri and K. S. Anseth, *Adv. Healthcare Mater.*, 2017, **6**, 1700254.
- 36 K. J. Greenlee, Z. Werb and F. Kheradmand, *Physiol. Rev.*, 2007, **87**, 69–98.
- 37 K. Masumoto, J. D. De Rooij, S. Suita, R. Rottier, D. Tibboel and R. R. De Krijger, *Histopathology*, 2005, **47**, 410–419.
- 38 D. R. Griffin, W. M. Weaver, P. O. Scumpia, D. Di Carlo and T. Segura, *Nat. Mater.*, 2015, **14**, 737–744.
- 39 Institute for Laboratory Animal Research, Guide for the Care and Use of Laboratory Animals, National Academies Press, Washington (DC), 8th edn, 2011.
- 40 Z. Salehi, H. H. Ghahfarokhi, A. A. Kodadadi and R. Rahimnia, *J. Ind. Eng. Chem.*, 2016, **35**, 224–230.
- 41 I. f. L. A. Research, 2011.
- 42 K. Hasegawa, A. Sato, K. Tanimura, K. Uemasu, Y. Hamakawa, Y. Fuseya, S. Sato, S. Muro and T. Hirai, *Respir. Res.*, 2017, **18**, 1–13.
- 43 J. A. Zepp, W. J. Zacharias, D. B. Frank, C. A. Cavanaugh, S. Zhou, M. P. Morley and E. E. Morrissey, *Cell*, 2017, 1134–1148.e10.
- 44 T. Kobayashi, S. Hattori and H. Shinkai, *Acta Derm.-Venereol.*, 2003, **83**, 105–107.
- 45 T. K. L. Meyvis, S. C. De Smedt, J. Demeester and W. E. Hennink, *J. Rheol.*, 1999, **43**, 933–950.
- 46 M. Rubinstein and R. H. Colby, *Polymer Physics*, Oxford University Press, New York, 2003.
- 47 P. Brûlet, C. Babinet, R. Kemler and F. Jacob, *Proc. Natl. Acad. Sci. U. S. A.*, 1980, **77**, 4113–4117.
- 48 E. R. Weibel, *Cell Tissue Res.*, 2017, **367**, 413–426.
- 49 T. Hayashi, W. Stetler-Stevenson, M. Fleming, N. Fishback, M. Koss, L. Liotta, V. Ferrans and W. Travis, *Am. J. Pathol.*, 1996, **149**, 1241–1256.
- 50 D. L. Matera, K. M. DiLillo, M. R. Smith, C. D. Davidson, R. Parikh, M. Said, C. A. Wilke, I. M. Lombaert, K. B. Arnold, B. B. Moore and B. M. Baker, *Sci. Adv.*, 2020, **6**, eabb5069, DOI: [10.1126/sciadv.abb5069](https://doi.org/10.1126/sciadv.abb5069).
- 51 A. Pardo, S. Cabrera, M. Maldonado and M. Selman, *Respir. Res.*, 2016, **17**, 1–10.
- 52 F.-Y. Lin and C.-C. Lin, *ACS Macro Lett.*, 2021, 341–345.
- 53 H. Shih and C.-C. Lin, *Biomacromolecules*, 2012, **13**, 2003–2012.
- 54 C. L. Petrou, T. J. D'Ovidio, D. A. Bölükbas, S. Tas, R. D. Brown, A. Allawzi, S. Lindstedt, E. Nozik-Grayck, K. R. Stenmark, D. E. Wagner and C. M. Magin, *J. Mater. Chem. B*, 2020, **8**, 6814–6826.
- 55 A. P. Epa, T. H. Thatcher, S. J. Pollock, L. A. Wahl, E. Lyda, R. M. Kottmann, R. P. Phipps and P. J. Sime, *PLoS One*, 2015, **10**, e0135266, DOI: [10.1371/journal.pone.0135266](https://doi.org/10.1371/journal.pone.0135266).
- 56 I. T. Stancil, J. E. Michalski, D. Davis-Hall, H. W. Chu, J.-A. Park, C. M. Magin, I. V. Yang, B. J. Smith, E. Dobrinskikh and D. A. Schwartz, *Nat. Commun.*, 2021, **12**, 4566.
- 57 K. K. Kim, M. C. Kugler, P. J. Wolters, L. Robillard, M. G. Galvez, A. N. Brumwell, D. Sheppard and H. A. Chapman, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 13180–13185.
- 58 Y. Kobayashi, A. Tata, A. Konkimalla, H. Katsura, R. F. Lee, J. Ou, N. E. Banovich, J. A. Kropski and P. R. Tata, *bioRxiv*, 2019, DOI: [10.1101/855155](https://doi.org/10.1101/855155).
- 59 K.-D. Alysandratos, C. G. d. A. Rivas, C. Yao, P. Pessina, C. Villacorta-Martin, J. Huang, O. T. Hix, K. Minakin, B. Konda, B. R. Stripp, C. F. Kim and D. N. Kotton, *bioRxiv*, 2022, DOI: [10.1101/2022.02.08.479591](https://doi.org/10.1101/2022.02.08.479591).
- 60 P. J. Wolters, H. R. Collard and K. D. Jones, *Annu. Rev. Phytopathol.*, 2014, **9**, DOI: [10.1146/annurev-pathol-012513-104706](https://doi.org/10.1146/annurev-pathol-012513-104706).
- 61 S. T. Magness, R. Bataller, L. Yang and D. A. Brenner, *Hepatology*, 2004, **40**, 1151–1159.
- 62 F. Liu, J. D. Mih, B. S. Shea, A. T. Kho, A. S. Sharif, A. M. Tager and D. J. Tschumperlin, *J. Cell Biol.*, 2010, **190**, 693–706.
- 63 K. A. Kyburz and K. S. Anseth, *Acta Biomater.*, 2013, **9**, 6381–6392.
- 64 J. A. Burdick and K. S. Anseth, *Biomaterials*, 2002, **23**.
- 65 N. F. Truong, E. Kurt, N. Tahmizyan, S. C. Leshner-Pérez, M. Chen, N. J. Darling, W. Xi and T. Segura, *Acta Biomater.*, 2019, **94**, 4315–4323.
- 66 W. Chang, K. Wei, L. Ho, G. J. Berry, S. S. Jacobs, C. H. Chang and G. D. Rosen, *PLoS One*, 2014, **9**, e106155.
- 67 A. J. Booth, R. Hadley, A. M. Cornett, A. A. Dreffs, S. A. Matthes, J. L. Tsui, K. Weiss, J. C. Horowitz, V. F. Fiore, T. H. Barker, B. B. Moore, F. J. Martinez, L. E. Niklason and E. S. White, *Am. J. Respir. Crit. Care Med.*, 2012, **186**, 866–876.
- 68 J. Yang, X. Pan, L. Wang and G. Yu, *Mol. Med.*, 2020, DOI: [10.1186/s10020-020-00223-w](https://doi.org/10.1186/s10020-020-00223-w).
- 69 H. Katsura, Y. Kobayashi, P. R. Tata and B. L. M. Hogan, *Stem Cell Rep.*, 2019, 657–666.
- 70 M. Lehmann, M. Korfei, K. Mutze, S. Klee, W. Skronska-Wasek, H. N. Alsafadi, C. Ota, R. Costa, H. B. Schiller, M. Lindner, D. E. Wagner, A. Günther and M. Königshoff, *Eur. Clin. Respir. J.*, 2017, **50**, 1602367.
- 71 M. Chilosi, A. Carloni, A. Rossi and V. Poletti, *J. Lab. Clin. Med.*, 2013, **162**, 156–73.
- 72 G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford and G. Oster, *Am. J. Respir. Crit. Care Med.*, 2006, **174**, 810–816.